NorstellaLinQ powers MMIT to help life sciences teams illuminate the path to patient access. By leveraging industry-leading data, cutting-edge technology and expert insights, MMIT transforms 74 billion data points into insights that power payer strategy,
Bringing a drug to market is a complex journey, with critical decisions at every stage. Learn how MMIT can partner with your team to help your brand succeed in our latest infographic.
In this use case, find out how MMIT, using NorstellaLinQ, developed a robust, unified dataset to provide comprehensive insights into a potential addressable rare disease population.
In this webinar, learn how best practices for targeting and engaging physicians both in-person and via non-personal promotion techniques.
Data is only powerful when it’s actionable. At MMIT, we analyze massive real-world datasets and translate the results into information your team can use. In this infographic, see how our RWD Insights can answer your
Learn how one manufacturer used integrated claims, lab, EMR and coverage data to identify newly diagnosed, early-stage cancer patients for just-in-time HCP targeting.
In this use case, learn how MMIT, powered by NorstellaLinQ, translated complex RWD into actionable strategies to help the client achieve business growth while advancing equity and patient access.
In this use case, learn how MMIT, powered by NorstellaLinQ, translated complex RWD into actionable insights which helped the client tackle affordability and access challenges in a complex therapeutic area.
In this use case, learn how MMIT Analytics enabled clinicians to easily identify covered alternatives when a drug was not approved, ensuring continuity in patient care.
In this use case, learn how the company used MMIT’s API to get access to formulary, medical policy, and restriction data, helping the client integrate this information into their existing software platform.
Learn how a small biopharma company used MMIT’s Analytics and Surveillance products to engage payers, educate providers and secure coverage for its rare disease therapy.
Learn how one national payer uses MMIT data to track market share, understand the depth and breadth of competitor offerings, and identify new opportunities for growth.
In the immediate post-launch timeframe, pharma companies can use market access research to improve coverage and utilization. In this webinar, our experts explain the benefits of everything from post-label indication research to competitor analyses and
Learn how one pharma company used MMIT’s solutions to target the right payers and physicians, improving patient access to its ophthalmic therapies.
In this webinar, MMIT’s Steve Callahan and AssistRx’s Brok Vandersteen discuss the payer, regulatory and market updates that will impact patient services’ financial assistance programs in 2025.
Download case studies that demonstrate how a variety of pharma companies use MMIT’s powerful Analytics platform to access comprehensive formulary, medical policy and restriction information with easy-to-use technology.
Download the brochure to learn more about how Medical Drug Lists can help your team.
Download the brochure to learn more about how RC Claim Assist can help your team.
This case study details how a mid-size pharma company improved its launch dashboards with an API from MMIT.
Learn how to place MMIT’s real-time coverage data on your website with daily updates, backed by our trusted API technology support.
With ReimbursementCodes, your team will gain access to a normalized dataset of industry standard specialty drug pricing, coding and clinical data. This information will streamline your operations and lead to a decrease in errors.
Learn how MMIT’s Application Programming Interface (API) technology allows organizations to seamlessly ingest and integrate our industry-leading data into their own data warehouse.
Download the brochure to see how obtaining a current, validated source of truth for payer contact information and PBM contact information will help your team reach top targets.
In this webinar, learn what kinds of market access research pharma companies should complete in the six to twelve months before launch to strengthen their performance.
In this infographic, learn how MMIT’s personal and non-personal promotional solutions help pharma companies identify and engage key physicians with consistent cross-channel messaging.
This case study explains how one regional payer leveraged MMIT’s Fee Scheduler solution to simplify methodology review, speed claim verification and improve workflow.
MMIT’s Payer Landscape is an easy-to-navigate application that enables account managers to segment payers by market share, line of business, geographic reach and key relationships.
The Directory of Health Plans provides comprehensive enrollment data to power your strategies.
Download this brochure to see how MMIT’s Coverage Search application enables field teams to deliver brand-specific messaging to HCPs and address any access questions that they have.
Improve decision making with a forward-looking analysis into access management topics and therapeutic area management, sourced directly from payers, HCPs, and practice managers representing 75% of Commercial & Medicare lives.
MMIT IDN Formulary Insights provides unparalleled visibility into health system formularies, clinical pathways, decision-making and contracting to enable superior market performance with these complex stakeholders.
With Custom Market Research you can gain actionable insight across stakeholders such as payers, IDNs and physicians for strategic planning and forecasting activities related to managed care, payer access, reimbursement, patient satisfaction, and access dynamics.
This case study details how Peregrine Market Access leveraged MMIT’s Analytics and FormTrak solutions to help one pharma company spread the news about its product’s coverage to healthcare providers.
In this BioPharma Dive webinar, Dinesh Kabaleeswaran, SVP of Consulting and Advisory Services at MMIT, and Jen Klarer, partner and head of Cell & Gene Therapy at The Dedham Group, explain the results of our
Learn how to track drug launch performance across payers during the first critical months post-launch.
Learn how your team can validate formulary and medical benefit positioning at scale to reduce rebate leakage.
Learn how MMIT’s powerful Analytics platform allows you to access comprehensive formulary, medical policy and restriction information with easy-to-use technology.
Learn more about the newest offering from RJ Health, Fee Scheduler.
This webinar details how and why manufacturers benefit from early market research, using client use cases to show how planning for potential access scenarios leads to greater utilization at launch.
Learn how one small biopharma company achieved 95% payer coverage for its rare disease therapy using MMIT’s strategic data solutions.
Download the brochure to learn how your team can benefit from MMIT’s custom P&T Perspectives offering.
Download the brochure to learn how your team can benefit from MMIT’s Message Monitor.
Download the brochure to learn how your team can benefit from MMIT’s new HCP Message Monitor offering.
Our three solutions—Rapid Response, Rapid IDIs, and Engage—provide quick, relevant insights for your brand.
Definitive insights for validation and strategic decision making in a condensed timeline.
MMIT’s first-annual industry survey sheds light on the current and future patient access landscape.
Learn more about MMIT’s FormTrak integration with Veeva CRM.
Our industry standard data can answer your top business questions. Learn how our data files can help your team.
Real-world data informs pharma companies’ decision-making across the development lifecycle. In this infographic, see what percentage of manufacturers are using RWD in each phase, and for what purposes.
Each area of clinical advancement—from precision medicine to immunology to radiotherapeutics—has its own access barriers. In this infographic, see the roadblocks specific to each therapeutic area, and learn how manufacturers can help patients overcome them.
Learn how one small biopharma company used MMIT’s claims, coverage and restriction data to better understand payer mix and utilization analytics in preparation for the successful launch of its oncology combination therapy.
Learn how one small pharma company used MMIT to understand how payers viewed their product and its competitors and communicate coverage changes to providers.
Download the brochure to learn how MMIT’s HCP Targeting Reports deliver net-new NPIs treating patients eligible for your therapy.
Download the brochure to learn how your team can predict payer and PBM uptake for your new brand with precision.
Learn how MMIT’s newest offering, HCP Message Monitor, helped a pharmaceutical manufacturer enhance brand messaging by evaluating HCP understanding and recall.
Learn more about MMIT’s proactive, economic, precise, and comprehensive solution that can help manufacturers promote their therapies to specific providers using lab test results before a diagnosis and/or prescribing decision is made.
This ebook unpacks the complexities of market access to ensure your team is prepared for a successful launch of your medical benefit therapy. With a solid foundational knowledge and a data-driven game plan, your team
Learn how one pharma company leveraged MMIT’s Analytics solution, FormTrak and Coverage Search tools to drive sales impact.
Learn why FormTrak’s integration in Veeva CRM is used by 25 organizations to help field reps and brand managers promote 46 brands.
To eliminate access barriers, manufacturers need more than the traditional coverage and restriction data. This webinar addresses how and why market access is broadening to include patient-level data and analytics.
This ebook unpacks the complexities of market access to ensure your team is prepared for a successful launch of your pharmacy benefit therapy. With a solid foundational knowledge and a data-driven game plan, your team
Learn how one rare disease manufacturer leveraged MMIT’s Analytics solution and Payer Landscape platform to identify coverage changes and build stronger payer relationships.
Learn how one pharma company used immediate payer feedback on off-label coverage decisions to help it determine whether to seek a new FDA indication.
Learn what sets FormTrak apart and why it is the best solution on the market, helping pharma companies share real-time payer coverage information with healthcare providers.
In a recent BioPharma Dive webinar, three industry experts discussed how integrated RWD can help pharma companies understand and improve the patient treatment journey.
Whether new clinical results support your brand or a new competitor is challenging it, rapid turn-around market research can help enhance manufacturers’ understanding of key market events or unexpected changes in the market.
Learn more about MMIT Analytics and how it can benefit your organization.
Integrated RWD from claims, labs, and other sources is instrumental to a successful market access strategy. This executive summary of a BioPharma Dive webinar explains how RWD helps manufacturers uncover and resolve patient access barriers.
Learn how a manufacturer used MMIT’s custom market research to assess the value of their product in the asthma treatment space and address unmet marketplace needs.
Learn how a manufacturer used MMIT’s custom market research to find how their product would be assessed during the clinical and financial review portions of a P&T session.
Learn how a manufacturer used MMIT’s custom market research to determine how it’s viewed in the marketplace in a variety of categories across time and against analog companies.
Learn how a manufacturer used MMIT’s custom market research to inform launch pricing and access strategy for their new product.
Learn how KORU Medical Systems used claims and payer coverage data to better understand reimbursement and improve patient access to its devices.
Give your messaging more impact with MMIT’s Custom Communication Program + Message Monitor.
Learn how one biopharma company prepared for a new competitor by analyzing past market analogs and sales trends.
Learn how MMIT helps life sciences companies use real-world data to get lifesaving therapies in the hands of more patients and physicians.
Learn how MMIT collects and analyzes real-world data and transforms it into actionable insights.
MMIT’s real-world data solution uses multiple data points and insights to help manufacturers understand each step of the patient journey.
MMIT’s real-world data solution provides critical insights for manufacturers across the clinical and commercial life cycle.
Payer Landscape provides organizations across healthcare a simple way to understand and segment health plan accounts by lives, channel and geography.
The Directory of Health Plans (DHP) provides organizations across healthcare with current and comprehensive health plan enrollment data.
A pharma company with several approved brands with large market share was developing a new Crohn’s disease drug. The company partnered with MMIT to determine whether the new drug would be approved in the marketplace
Learn more about MMIT’s Multi Channel Message Testing solution.
Learn more about MMIT’s Payer Messaging Playbook solution.
Learn how one biotech company used MMIT’s Analytics, Surveillance, FormTrak and Coverage Search tools to achieve its launch goals early.
Learn how a healthcare IT organization was able to gain a deeper understanding of their market potential and obtain competitive intelligence with Payer Landscape.
Download our infographic to learn the depth of information you can access with our newest databases.
Your team needs a variety of resources to develop a successful payer strategy. Download this infographic to learn how MMIT can help your organization.
Connecting with the right healthcare stakeholders about your brand is difficult. Learn how RJ Health, an MMIT company, can make it simpler.
Learn how a P&T review helped one pharma company understand how its product would be assessed, leading to a new focus on gathering real-world evidence.
Hear from pharmaceutical companies already using Contract Validation about how the solution has changed their workflow.
Gain comprehensive insight into formulary and medical benefit coverage, covered lives, and policy and restriction information.
Learn more about MMIT’s RC Claim Assist solution.
Learn more about MMIT’s Rapid Response solution.
Learn more about MMIT’s Engage solution.
Our Patient and Office Staff Satisfaction Surveys provide objective benchmarking data to help specialty pharmacies improve their performance, gain accreditation, and win payer and manufacturer contracts.
Open to learn why MMIT’s Lab Data is the best solution for longitudinal tracking of patients.
RJ Health, an MMIT company, conducted a survey on NDC mandates. In 2016 and 2021, we asked payers questions such as how they are managing NDCs and who performs unit conversions. We compiled these results
Learn more about MMIT’s Bridging as a Service solution.
Contracting in pharma has grown increasingly complex, which results in significant rebate leakage for manufacturers. Recent MMIT research highlights the severity of the problem.
How MMIT’s longstanding advisory relationship with a global pharmaceutical company helped transform its portfolio strategy.
Learn how pharma companies that were early adopters of MMIT’s FormTrak integration in Veeva CRM see the new functionality changing their workflow.
Understanding and maintaining insight into payer enrollment is difficult. At MMIT, we are focused on helping our clients understand the complex payer landscape.
How Medical Billing and Coding Can Impact Patient Access. Hear from the experts from RJ Health, an MMIT company.
Patient assistance programs can have an enormous impact on the time-to-treatment for prescribers and patients. Your ability to establish a patient assistance program strategy, especially when there are barriers to prescribing.
Learn how a pharma company leveraged MMIT’s Strategic Launch Report combined with In-Depth Interviews to get a unique view into the market access path for its therapy.
Learn more about MMIT’s Surveillance solution.
Learn how a product’s placement on pathways affects its utilization and uptake, and ultimately, patient’s access to life saving therapies.
Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.
MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
Learn how MMIT and MarketLauncher helped a medtech company engage a difficult-to-reach health plan audience.
Learn more about MMIT’s Formulary Navigator solution.
Learn how RJ Health helped a niche healthcare company bolster its payer communications.
Learn how a data-driven market access strategy and competitor benchmarking led to launch excellence.
Contract Validation is a workflow automation platform that enables manufacturers to validate formulary positioning at scale by crosschecking the contract language against MMIT’s industry-leading data.
MMIT’s FormTrak tool helps prescribers get their patients on the right therapy even amid complex drug coverage requirements. FormTrak’s integration in Veeva CRM, pharma field teams can deliver an access message right in Veeva’s platform.
MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
Learn how a small pharma company leveraged MMIT’s Analytics platform to drive its messaging with healthcare providers as it launched its first commercial product at the start of the COVID-19 pandemic.
Learn how a pharma company partnered with MMIT’ to understand payer perceptions of its brand over time as competitors enter the market.
Learn how a pharma company preparing for a drug launch partnered with MMIT to gain insight into the most effective messaging with payers.
Understanding a large complex payer and their subsidiaries to segment your contracting plan or recognizing lives enrollment shifts in specific geographies, having payer data source solution to support your sales and marketing team is crucial.
Payer coverage policies continue to become more complex with increasing access hurdles. Dig into ways to sift through the noise and uncover payer account intervention and pull-through opportunities via dashboards and real-time alerts.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
Learn how formularies are currently managed, examine some of the key challenges faced by payers and PBMs, and evaluate new integrated solutions to optimize management of both pharmacy and medically covered drugs.
Learn how a pharma company’s market access team leveraged MMIT’s quantitative online surveys to obtain a custom pricing and contracting study to support its drug launch.
Factors complicate the payer enrollment landscape, making it challenging to project membership rolls across payers, geographies and channels. See enrollment projections, the drivers behind them and what you can expect from the 2021 payer landscape.
Learn how claims reimbursement is currently being managed, as well as some best practices for leveraging specialty drug data to streamline the process.
Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
Access barriers to the use of innovative technology such as administrative burden and reimbursement challenges. We will also touch upon payer concern about costs which might be underlying these issues.
Learn when and how to select the right analogs to set the most accurate expectations and payer strategy at launch.
Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.
Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.
Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.
Why aren’t pharma teams shifting market access strategies to earlier phases of drug development? The influence of payers and PBMs is often poorly understood.
MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.
P&T Session Heart Failure: MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.
P&T Session Heart Failure: MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.
P&T Session Heart Failure: MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.
P&T Session Heart Failure: MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.
View a demo of the Payer Landscape tool.
Description